目的 討89Sr治療肺癌多發(fā)骨轉移的臨床療效。方法 30例肺癌多發(fā)骨轉移患者予以肘靜脈注射89SrCl2 148 MBq/例次，治療后第28 d，觀察疼痛強度（通過劃線法和止痛藥的使用情況評價），通過同位素全身骨掃描骨轉移灶數目、尿吡啶酚（PYD）和脫氧吡啶酚（DPD）水平的變化進行療效評價。結果 與治療前比較，治療28 d后疼痛強度顯著緩解(P lt;0.001)，疼痛緩解率73.3%，消失率16.6%。骨轉移灶數目減少16例，有效率53.3%，改善程度明顯（P lt;0.001）。PYD和DPD較治療前明顯下降[（62.48±37.25）比（100.15±48.65）nmol/mmol Cr，（13.94±8.66）比（31.25±15.32）nmol/mmol Cr，P均 lt;0.001]。結論 89Sr可有效緩解肺癌多發(fā)骨轉移的骨痛，減少骨轉移灶數量，提高患者生活質量。
引用本文： 胥杰,陳曉. 89Sr治療30例肺癌多發(fā)骨轉移的療效觀察. 中國呼吸與危重監(jiān)護雜志, 2008, 08(2): 104-106. doi: 復制
| 1. | Ashayeri E,Omogbehin A,Sridhar R,et al.Strontium 89 in the treatment of pain due to diffuse osseous metastases:a university hospital experience.J Natl Med Assoc,2002,94:706-711. |
| 2. | 郭永忠,張峰.尿脫氧吡啶酚是新的骨吸收生化指標.醫(yī)學綜述,2000,6:7-9. |
| 3. | Finlay IG,Mason MD,Shelley M.Radioisotopes for the palliation of metastatic bone cancer:a systematic review.Lancet Oncol,2005,6:392-400. |
| 4. | Ron IG,Stav O,Vishne T,et al.The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases.Am J Clin Oncol,2004,27:500-504. |
| 5. | Lam MG,de Klerk JM,van Rijk PP,et al.Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases.Anticancer Agents Med Chem,2007,7:381-397. |
- 1. Ashayeri E,Omogbehin A,Sridhar R,et al.Strontium 89 in the treatment of pain due to diffuse osseous metastases:a university hospital experience.J Natl Med Assoc,2002,94:706-711.
- 2. 郭永忠,張峰.尿脫氧吡啶酚是新的骨吸收生化指標.醫(yī)學綜述,2000,6:7-9.
- 3. Finlay IG,Mason MD,Shelley M.Radioisotopes for the palliation of metastatic bone cancer:a systematic review.Lancet Oncol,2005,6:392-400.
- 4. Ron IG,Stav O,Vishne T,et al.The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases.Am J Clin Oncol,2004,27:500-504.
- 5. Lam MG,de Klerk JM,van Rijk PP,et al.Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases.Anticancer Agents Med Chem,2007,7:381-397.